The present analysis sheds light on the cost-effectiveness of alternative Hb treatment targets and indicates that achieving a target Hb of 10.5 g/dl is most cost-effective in a cohort of people with CKD stages 3–4. The gene discussed is GSTM1; the disease is chronic kidney disease.